Cost Effectiveness of Paliperidone for Schizophrenia in Greece
Author Information
Author(s): Geitona Maria, Kousoulakou Hara, Ollandezos Markos, Athanasakis Kostas, Papanicolaou Sotiria, Kyriopoulos Ioannis
Primary Institution: Department of Economics, University of Thessaly
Hypothesis
To compare the costs and effects of paliperidone extended release with other oral antipsychotic agents in patients with schizophrenia in Greece.
Conclusion
Treatment with paliperidone ER can lead to lower total cost and higher number of stable days in most of the cases examined.
Supporting Evidence
- Paliperidone ER resulted in 272.5 stable days compared to 272.2 for olanzapine.
- Paliperidone ER had a lower total cost of €7,030 compared to other treatments.
- The study was conducted from the perspective of the Greek National Health System.
Takeaway
This study found that using paliperidone ER for schizophrenia is cheaper and helps patients feel better for more days compared to other medications.
Methodology
A decision tree model was developed to analyze costs and effectiveness over a 1-year period.
Potential Biases
Potential bias from expert panel decisions which may reflect personal experiences rather than consensus.
Limitations
The study relied on expert opinion and lacked long-term comparative data from clinical studies.
Participant Demographics
Patients with schizophrenia experiencing acute exacerbation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website